tegretol mixtúra, dreifa 20 mg/ml
novartis healthcare a/s - carbamazepinum inn - mixtúra, dreifa - 20 mg/ml
tegretol tafla 200 mg
novartis healthcare a/s - carbamazepinum inn - tafla - 200 mg
tegretol retard forðatafla 200 mg
novartis healthcare a/s - carbamazepinum inn - forðatafla - 200 mg
tegretol retard forðatafla 400 mg
novartis healthcare a/s - carbamazepinum inn - forðatafla - 400 mg
metoprolol alvogen (metoprolol ratiopharm) forðatafla 95 mg
alvogen ehf. - metoprololum súkkínat - forðatafla - 95 mg
metoprolol alvogen (metoprolol ratiopharm) forðatafla 190 mg
alvogen ehf. - metoprololum súkkínat - forðatafla - 190 mg
clarithromycin alvogen (clarithromycin ratiopharm) filmuhúðuð tafla 500 mg
alvogen ehf. - clarithromycinum inn - filmuhúðuð tafla - 500 mg
metoprolol alvogen (metoprolol ratiopharm) forðatafla 23,75 mg
alvogen ehf. - metoprololum súkkínat - forðatafla - 23,75 mg
metoprolol alvogen (metoprolol ratiopharm) forðatafla 47,5 mg
alvogen ehf. - metoprololum súkkínat - forðatafla - 47,5 mg
mircera
roche registration gmbh - metoxý annara hættu efst-epóetín beta - anemia; kidney failure, chronic - sýklalyf - treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adult patients (see section 5. treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in paediatric patients from 3 months to less than 18 years of age who are converting from another erythropoiesis stimulating agent (esa) after their haemoglobin level was stabilised with the previous esa (see section 5.